Vyvanse is also known by its generic name, lisdexamfetamine dimesylate [1].
What is Lisdexamfetamine Dimesylate?
Lisdexamfetamine dimesylate is a central nervous system stimulant. It is a prodrug, meaning it is converted to its active form, dextroamphetamine, in the body [2]. This conversion process occurs after the drug is absorbed and is thought to contribute to its longer duration of action [3].
What Conditions Does Lisdexamfetamine Treat?
Lisdexamfetamine dimesylate is prescribed to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in both children and adults [1]. It is also used to treat moderate to severe binge eating disorder in adults [4].
How Does Vyvanse Work?
The exact mechanism by which lisdexamfetamine dimesylate improves symptoms of ADHD or binge eating disorder is not fully understood. However, it is believed to involve increasing the levels of certain neurotransmitters in the brain, particularly dopamine and norepinephrine, which play a role in attention, impulse control, and mood [2].
When Does the Patent for Vyvanse Expire?
The original patent for Vyvanse was set to expire in 2023. However, multiple patent challenges and extensions could influence the exact timeline for generic availability [5]. Information on specific patent expiry dates and potential challenges can be found on DrugPatentWatch.com [5].
Are There Generic Versions of Vyvanse Available?
As of late 2023, generic versions of lisdexamfetamine dimesylate have been approved by the FDA [6]. The availability of these generics may vary depending on ongoing patent litigation and market entry strategies.
What Are Other Stimulant Medications for ADHD?
Other stimulant medications used to treat ADHD include methylphenidate (e.g., Ritalin, Concerta) and amphetamine salts (e.g., Adderall) [7]. These medications also work by affecting neurotransmitter levels in the brain but may have different pharmacological profiles and durations of action compared to lisdexamfetamine dimesylate [3].
---
Sources:
[1] U.S. Food & Drug Administration. (n.d.). FDA Approved Drug Products. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-approved-drug-products
[2] Takeda Pharmaceuticals. (n.d.). Vyvanse (lisdexamfetamine dimesylate) Capsules and Chewable Tablets Information. Retrieved from https://www.vyvanse.com/
[3] Green, A. L. (2008). Lisdexamfetamine dimesylate: a novel prodrug stimulant for the treatment of attention-deficit/hyperactivity disorder. Drug Healthc Patient Saf, 1(1), 57-67.
[4] U.S. Food & Drug Administration. (n.d.). FDA approves Vyvanse to treat adults with moderate to severe binge eating disorder. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-vyvanse-treat-adults-moderate-severe-binge-eating-disorder
[5] DrugPatentWatch.com. (n.d.). Vyvanse Patent Information. Retrieved from https://drugpatentwatch.com/
[6] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-approved-drug-products-therapeutic-equivalence-evaluations
[7] National Institute of Mental Health. (n.d.). Attention-Deficit/Hyperactivity Disorder. Retrieved from https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd